EU regulator begins real-time review of first Chinese COVID-19 vaccine

# 14:38
4 May 2021

Europe's medicines regulator said on Tuesday it has started a real-time review of Sinovac's (SVA.O) COVID-19 vaccine, based on preliminary results from animal and human trials that suggested the vaccine produces an immune response against the coronavirus, APA reports citing Reuters.

Data on the vaccine, COVID-19 Vaccine (Vero Cell) Inactivated, will be assessed as they are made available to help speed up potential approvals, the European Medicines Agency (EMA) said.

This is the first Chinese vaccine the EMA is studying in real-time, and the fourth COVID-19 vaccine under such a review, including those from CureVac , Novavax Inc (NVAX.O) and Russia's Sputnik V.

Sinovac's vaccine has shown efficacy rates between 50% and 90% in different studies and is currently authorised for use in China, Indonesia, Brazil and Turkey.